Actively Recruiting

Age: 18Years +
All Genders
ID06940102

A Multicenter Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in Patients With Advanced Digestive System Tumors Receiving TKI-Based Therapy

Led by Changchun GeneScience Pharmaceutical Co., Ltd. · Updated on 2025-04-23

120

Participants Needed

2

Research Sites

39 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to evaluate the effectiveness of Nano-crystalline Megestrol Acetate for treating cachexia in patients with advanced digestive system tumors who are receiving TKI-based therapy. The study focuses on patients with cancers such as gastric cancer, colorectal cancer, and hepatocellular carcinoma, particularly those with advanced or metastatic disease not suitable for curative treatment. The trial is observational and conducted in a real-world setting to observe the treatment's impact. Participants will either receive Nano-crystalline Megestrol Acetate oral suspension at a dose of 625 mg per day combined with TKI therapy, which may also include chemotherapy or immunotherapy, or they will receive TKI-based therapy alone. The treatment period lasts 12 weeks, during which the effects on appetite and weight will be closely monitored. This study does not involve randomization or blinding. During the study, participants will be assessed for improvements in appetite and weight from the start to the end of the 12-week treatment period. Researchers will also track progression-free survival for up to 24 months. Assessments will include clinical evaluations and monitoring of organ function to ensure safety. The total participation time includes the 12-week treatment and extended observation for disease progression, with regular follow-up visits throughout the study duration.

CONDITIONS

Brief Title

Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Voluntarily sign a written informed consent.
  • Be 18 years of age or older.
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
  • Have a life expectancy of at least 3 months.
  • Have histologically or cytologically confirmed locally advanced or metastatic digestive system tumors not suitable for curative treatment.
  • Not be benefiting from local anticancer therapies such as surgery, local ablation, or chemoembolization.
  • Be planned to receive TKI-based anticancer treatment, which may include chemotherapy or immunotherapy.
  • Meet the diagnostic criteria for pre-cachexia or cachexia based on Fearon criteria.
  • Have good organ function as determined by the study team.
Not Eligible

You will not qualify if you...

  • Have gastrointestinal obstruction.
  • Have anorexia caused by neurosis, mental illness, or pain affecting eating.
  • Have severe cerebrovascular, cardiac, renal, or liver diseases.
  • Have had major surgery or trauma within the last month.
  • Have allergy to any component of the investigational drug.
  • Have other conditions considered unsuitable by the investigator.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Up to 12 weeks

Participants receive Nano-crystalline Megestrol Acetate Oral Suspension along with TKI-Based Therapy for cachexia in advanced digestive tumors.

Periodic visits during the 12-week treatment period

Follow-up

Duration - Up to 24 months

Participants are monitored for progression-free survival and other outcomes after the treatment period.

Follow-up visits as determined by the study team

Trial Site Locations

Total: 2 locations

1

General Hospital of Northern Theater Command

Shenyang, Liaoning, China, 110016

Actively Recruiting

2

Liaoning Cancer Hospital

Shenyang, Liaoning, China, 110042

Actively Recruiting

Loading map...

Research Team

C

Cheng Du

Z

Zhenguang Du

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

Phase III Randomized Controlled Trial Comparing D2 Versus D3...

Gastric Cancer

Actively Recruiting

1 location

A Phase 1/2a Study of the Safety, Tolerability, and Prelimin...

Castration-Resistant Prostate Cancer (CRPC)

Actively Recruiting

4 locations

Clinical Impact of 18F-FDGal PET/CT and PET/MRI in Patients ...

Hepatocellular Carcinoma

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here